GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Igene Biotechnology IGNE · USD

Materials · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2009

Revenue

$4.0m

FY2009FY2009

Net income

−$140,747

FY2009FY2009

Free cash flow

−$268,828

FY2009FY2009

Shareholders' equity

−$2.7m

FY2009FY2009

Income statement

Fiscal years

FY2009
Revenue$4.0m
Gross profit$1.0m
Research and development$1.9m
Operating income−$1.1m
Net income−$140,747
Diluted earnings per share-0.00

Balance sheet

At each fiscal year end

FY2009
Total assets$4.8m
Cash and short-term investments$1.3m
Total liabilities$7.5m
Debt$6.8m
Shareholders' equity−$2.7m
Shares outstanding1,550m

Cash flow

Fiscal years

FY2009
Cash from operations−$97,049
Capital spending−$171,779
Free cash flow−$268,828

Latest quarters

By quarter end

Sept 2010Jun 2010Mar 2010Dec 2009Sept 2009Jun 2009Mar 2009Dec 2008
Revenue———$4,804$1.1m$1.6m$1.2m$1.4m
Gross profit———$40,847$654,318$23,798$296,600−$182,726
Operating income−$625,502−$822,069−$540,881−$343,171$151,211−$593,777−$284,132−$1.2m
Net income−$627,236−$811,212−$549,047−$386,387$114,808−$601,906$732,738−$1.4m
Diluted earnings per share-0.00-0.00-0.00-0.000.00-0.000.00-0.00
Cash from operations—————$1.0m——
Total assets$3.4m$4.0m$4.6m$4.8m$5.7m$5.1m$5.4m$6.1m
Cash and short-term investments$269,290$977,381$1.3m$1.3m$2.6m$1.5m$937,558$1.5m
Debt$1.6m$1.6m$1.5m$1.1m$2.0m$912,086$588,210$354,000
Shareholders' equity−$4.7m−$4.1m−$3.2m−$2.7m−$2.4m−$2.5m−$1.9m−$2.7m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue——71.4%
Operating income37.0%—-5.3%
Net income-50.4%—-25.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin19.5%———
Operating margin-28.1%———
Net margin-35.6%———

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return0%0%-90%0%-50%567%757%666%908%150%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.